AGF Management Ltd. Decreases Stock Holdings in The Cooper Companies, Inc. (NASDAQ:COO)

AGF Management Ltd. lowered its stake in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 6.2% during the fourth quarter, Holdings Channel reports. The institutional investor owned 5,409 shares of the medical device company’s stock after selling 357 shares during the period. AGF Management Ltd.’s holdings in Cooper Companies were worth $497,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Covestor Ltd lifted its holdings in shares of Cooper Companies by 144.9% in the third quarter. Covestor Ltd now owns 338 shares of the medical device company’s stock valued at $37,000 after purchasing an additional 200 shares in the last quarter. Byrne Asset Management LLC purchased a new stake in shares of Cooper Companies in the fourth quarter valued at about $33,000. OFI Invest Asset Management purchased a new stake in shares of Cooper Companies in the fourth quarter valued at about $34,000. Brown Brothers Harriman & Co. lifted its holdings in shares of Cooper Companies by 191.0% in the third quarter. Brown Brothers Harriman & Co. now owns 419 shares of the medical device company’s stock valued at $46,000 after purchasing an additional 275 shares in the last quarter. Finally, West Financial Advisors LLC purchased a new stake in shares of Cooper Companies in the fourth quarter valued at about $49,000. Hedge funds and other institutional investors own 24.39% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Citigroup reduced their price target on shares of Cooper Companies from $115.00 to $110.00 and set a “buy” rating on the stock in a report on Friday, March 7th. JPMorgan Chase & Co. cut their price objective on shares of Cooper Companies from $120.00 to $110.00 and set an “overweight” rating for the company in a research report on Friday, March 7th. Piper Sandler reissued an “overweight” rating and issued a $115.00 price objective (down previously from $120.00) on shares of Cooper Companies in a research report on Friday, March 7th. StockNews.com lowered shares of Cooper Companies from a “buy” rating to a “hold” rating in a research report on Wednesday, December 11th. Finally, Morgan Stanley cut their price objective on shares of Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating for the company in a research report on Friday, December 6th. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, Cooper Companies has a consensus rating of “Moderate Buy” and a consensus target price of $111.89.

Cooper Companies Stock Performance

Shares of COO stock opened at $81.22 on Friday. The Cooper Companies, Inc. has a one year low of $77.05 and a one year high of $112.38. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.12 and a current ratio of 1.91. The company has a 50 day moving average price of $91.20 and a 200 day moving average price of $98.90. The firm has a market capitalization of $16.24 billion, a price-to-earnings ratio of 41.65, a price-to-earnings-growth ratio of 2.25 and a beta of 1.02.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings results on Thursday, March 6th. The medical device company reported $0.92 EPS for the quarter, hitting the consensus estimate of $0.92. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. The firm had revenue of $964.70 million during the quarter, compared to analyst estimates of $981.25 million. Sell-side analysts anticipate that The Cooper Companies, Inc. will post 3.98 EPS for the current year.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.